Navigation Links
New Report 'Looking at Chiral Technologies' Analyzes the Global,Market Growth Forecasts Driven By Two Very Important Components as,Single Isomer Drugs and Single Enantiomer Pharmaceuticals

DUBLIN, Ireland--(BUSINESS WIRE)--Jun 21, 2007 - Research and Markets (http://www.researchandmarkets.com/reports/c60415) has announced the addition of Looking at Chiral Technologies to their offering.

The advancements in molecular research and continued untiring efforts of the research industry to develop better more precisely applicable Pharmaceuticals as well as agro compounds would have not been possible without the advent of Chiral technologies and their applications.

The usage of chiral molecules is at the very centre of this technological revolution when coupled with the application of chiral technologies as: Chiral Pool, Resolution, Biocatalysts, or asymmetric analysis creates the required compounds. The majority of development activity is routed through fine chemical companies which are additionally trying to upgrade their capabilities in order to provide to the entire portfolio of pharmaceutical drugs for application in the consumer arena.

Such ramping up of operations by companies in order to develop and upgrade basic molecules for wide ranging applications is also bringing the focus of chiral technologies into the development of clinical cures.

This report - Looking at Chiral Technologies - introduces the concept of Chiral Technologies supplementing it with its variants and explaining the actions undertaken by the industry towards developing such compounds jointly and deriving common benefits of clinical nature. The report also analyzes the global market growth forecasts driven by two very important components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals which are synthesized in bulk nature which are contributing to deriving drug streams worldwide.

The report explains the sales of Single Enantiomer pharma on a YOY basis, which is being controlled by certain regulatory constraints. The report also presents an insight on the synergies developed by the industr
'"/>




Page: 1 2

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:5/21/2013)... 21, 2013 STAAR Surgical Company (NASDAQ: ... of minimally invasive ophthalmic products, today announced that it ... the Company,s recent financial results and business developments with ... present at the 38 th Annual Deutsche Bank ... at the Westin Waterfront Hotel on Wednesday, May 29, ...
(Date:5/20/2013)... , May 21, 2013 ... Assembly, where world,s health ministers gather to address the ... Mental and neurological disorders (MNDs) affect 700 million ... non-communicable disease (NCD) burden ,Do You Mind?, ... the role each can play to collectively address MNDs ...
(Date:5/20/2013)... , May 20, 2013 Landauer, Inc. ... personal and environmental radiation measurement and monitoring, outsourced medical ... today that its Board of Directors declared, at its ... dividend of $0.55 per share for the third quarter ... July 3, 2013, to shareholders of record on June ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
... dose of velafermin for the prevention ... path for belinostat in the ... treatment of cancer -, - Conference call and webcast to ... 6 CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage biopharmaceutical company focused on,oncology, ...
... with ... ImmuneRegen,s Adjuvant, SCOTTSDALE, Ariz., ... BioSciences Holdings, Inc.,(OTC Bulletin Board: IRBO), today announced it has ... VXGN.PK). As part,of the agreement, ImmuneRegen will receive the pharmaceutically ...
Cached Medicine Technology:CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 2CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 3CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 4CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 5CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 6CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 7CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs 8ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 2ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 3ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc. 4
(Date:5/21/2013)... Puroast® Low Acid Coffee has named former Johnson ... the Board. , Among the many key ... his more than 30-year career was as a member ... of Consumer Pharmaceuticals & Nutritionals and President of McNeil ... build the market for such brands as Splenda®, Lactaid®, ...
(Date:5/21/2013)... attack on glioblastoma brain tumor cells that uses a ... study to establish the proper dose level, researchers at ... Duke and tested in an ongoing phase 1 study, ... abundance of receptors that work like magnets drawing the ... , The investigational therapy, known as PVSRIPO, uses an ...
(Date:5/21/2013)... 21, 2013 Adeptia, a leading provider ... today announced it is the featured company in an ... Research. The report, “Adeptia Bets on Converged Cloud Integration ... company, its strategy, products, pricing, customers and competition. ... a framework for integration and process orchestration, especially when ...
(Date:5/21/2013)... , , TUESDAY, May 21 (HealthDay News) -- Depression can ... the changes brought about by the disorder can be ... has found that people with diabetes who are depressed ... having a severe low blood sugar (hypoglycemia) episode that ... diabetes who aren,t depressed. "Depression is a ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
Breaking Medicine News(10 mins):Health News:Former Johnson & Johnson Executive Brian Perkins Named Chairman of Puroast® Coffee 2Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:Adeptia Featured in Recent 451 Research Impact Report 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2
... to fund multiple sclerosis researchCHICAGO, April 6 The ... support for MS education and awareness by purchasing the ... March 4, 2009, the Lottery released "Dash! For Cash" ... For Cash" is the second instant game created to ...
... decision by the Centers for Medicare and Medicaid Services ... scans in the initial treatment strategy of patients with ... compelling clinical evidence of the effectiveness of PET for ... known as the National Oncologic PET Registry (NOPR). ...
... hopes for stem cell therapy, major structural and cultural changes ... in the UK. Currently the chances of getting effective treatments ... industry is at serious risk of ,market failure,. , These ... and adoption of stem cell therapy carried out by researchers ...
... Americans free and unique fitness tools to help reduce stress ... is a fact of life. However, with the declining economy ... stressed than ever and some are looking for solutions on ... honor of Stress Awareness Month, is offering people free and ...
... or fiber and other beneficial nutrientsGLENDALE, Calif., April 6 ... to benefit children during different stages of their growth ... Juice Immunity are fruit juice beverages made with ... filtered water to naturally lower the sugar and calorie ...
... Rating Based on Quality Accounting and ManagementFRANKLIN LAKES, ... wondering about the safety of their savings, Forbes ... MHS ) as one of "The 100 Most Trustworthy ... upon Audit Integrity,s ranking of corporate accounting and management ...
Cached Medicine News:Health News:Illinois Lottery Releases New MS Ticket, Dash! For Cash 2Health News:Illinois Lottery Releases New MS Ticket, Dash! For Cash 3Health News:SNM calls CMS PET scan decision a major benefit for cancer patients 2Health News:SNM calls CMS PET scan decision a major benefit for cancer patients 3Health News:Stem cell innovation at risk 2Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 2Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 3Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 4Health News:Beat Stress for Free: MSN Encourages Americans to Take It Out on the Treadmill 5Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 2Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 3Health News:From Early Brain Development to Digestive Health, New Juicy Juice Beverages Aid Children Through Different Stages of Growth and Development 4Health News:Forbes Counts Medco As One of The 'Most Trustworthy Companies' 2Health News:Forbes Counts Medco As One of The 'Most Trustworthy Companies' 3
... is a scientifically advanced nutritional formulation ... and full body health. MacularProtect Complete ... trial and other advanced research. It ... provides a broad foundation of antioxidants, ...
... OcularProtect is a scientifically ... support for visual and full ... 40 key nutrients, including a ... as FloraGLO lutein, lycopene and ...
Ocuvite® Lutein is an advanced antioxidant supplement formulated to provide nutritional support for the eye....
... vitamins, minerals, and antioxidants in ... ocular tissue, improves tear quality, ... the lens and retina of ... optimized to bring accelerated relief ...
Medicine Products: